A Polymorphism in leuS Confers Reduced Susceptibility to GSK2251052 in a Clinical Isolate of Staphylococcus aureus.

Authors :: Gupta A
Monteferrante C
Rasina D
Leitis G
Randall CP
Tomlinson JH
Jirgensons A
Goessens WH
Hays JP
O'Neill AJ
Source :: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2016 Apr 22; Vol. 60 (5), pp. 3219-21. Date of Electronic Publication: 2016 Apr 22 (Print Publication: 2016).
Publication Year :: 2016
Abstract: GSK2251052 is a broad-spectrum antibacterial inhibitor of leucyl tRNA-synthetase (LeuRS) that has been evaluated in phase II clinical trials. Here, we report the identification of a clinical isolate of Staphylococcus aureus that exhibits reduced susceptibility to GSK2251052 without prior exposure to the compound and demonstrate that this phenotype is attributable to a single amino acid polymorphism (P329) within the editing domain of LeuRS.<br /> (Copyright © 2016, American Society for Microbiology. All Rights Reserved.)

Subjects :: Bacterial Proteins genetics
Leucine-tRNA Ligase genetics
Leucine-tRNA Ligase metabolism
Staphylococcus aureus genetics
Staphylococcus aureus metabolism
Anti-Bacterial Agents pharmacology
Boron Compounds pharmacology
Polymorphism, Genetic genetics
Staphylococcus aureus drug effects

Full Text Access

Tools